Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Lyumjev ® ▼ (insulin lispro)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Lyumjev® ▼ (insulin lispro): Treprostinil Cardiovascular Effects
In Lyumjev formulation, the microdoses of treprostinil used as an excipient don’t induce cardiovascular effects.
In the formulation of Lyumjev, microdoses of treprostinil are used as an excipient to increase blood flow at the site of injection through localized vasodilation.1-4
At doses equivalent to 200 units of Lyumjev, treprostinil does not cause changes in
1. Leohr J, Pratt E, Heilmann C, et al. Treprostinil causes local vasodilation is well tolerated, and results in faster absorption of insulin lispro [abstract]. Diabetologia. 2017;60(suppl 1):S313. http://dx.doi.org/10.1007/s00125-017-4350-z
2. Leohr J, Pratt EJ, Heilmann C, et al. A novel insulin lispro formulation containing citrate and treprostinil demonstrates faster absorption and onset of insulin action in healthy subjects [abstract]. Diabetes. 2017;66(suppl 1):A253. http://dx.doi.org/10.2337/db17-890-1488
3. Pratt E, Leohr J, Heilmann C, et al. Treprostinil causes local vasodilation, is well tolerated, and results in faster absorption of insulin lispro [abstract]. Diabetes. 2017;66(suppl 1):A253. http://dx.doi.org/10.2337/db17-890-1488
treprostinil = Remodulin® (treprostinil) injection
URLi = ultra rapid lispro
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 06 August 2019